[EN] SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF [FR] DÉRIVÉS CYCLIQUES DE SULFONYLE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
摘要:
The invention provides novel sulfonyl cyclic derivatives, and compositions and methods of preparation and use thereof, that are useful in treating various diseases and disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, metabolic diseases, metastatic cancer, and ageing.
Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
申请人:The Liver Company Inc.
公开号:US11136290B2
公开(公告)日:2021-10-05
Provided is a compound of Formula (I):
wherein the variable groups are defined herein.
提供的是一种式 (I) 化合物:
其中变量组在此定义。
SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES
申请人:GILEAD SCIENCES, INC.
公开号:EP3796975A1
公开(公告)日:2021-03-31
[EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
申请人:UNIV MICHIGAN REGENTS
公开号:WO2021041866A1
公开(公告)日:2021-03-04
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.
[EN] SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] DÉRIVÉS CYCLIQUES DE SULFONYLE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
申请人:[en]LYSOWAY THERAPEUTICS, INC.
公开号:WO2023235305A2
公开(公告)日:2023-12-07
The invention provides novel sulfonyl cyclic derivatives, and compositions and methods of preparation and use thereof, that are useful in treating various diseases and disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, metabolic diseases, metastatic cancer, and ageing.